Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in ...

SÖDERTÄLJE, Sweden I August 18, 2025 I Anocca AB (‘Anocca’ or the ‘Company’), a leading clinical-stage T-cell immunotherapy company, has successfully raised ...

Let’s take a closer look at a few biotech stocks poised to benefit from this resurgence. Medicus Pharma Ltd. (NASDAQ: MDCX) is an emerging biotech and life sciences company with a global footprint ...